Therapy-Related-Myeloid-Neoplasm-Risk Score: a convenient score for therapy-related myeloid neoplasms risk assessment in adult cancer patients

TL;DR

A new risk score called TMNRS helps predict the chance of developing therapy-related myeloid neoplasms in cancer patients, based on factors like treatment history and autoimmune disease.

Contribution

The TMNRS is a novel, convenient risk assessment tool for predicting therapy-related myeloid neoplasms in cancer survivors.

Findings

TMNRS was developed using data from 970,390 cancer patients and includes chemotherapy, radiation, autoimmune disease, and G-CSF exposure as predictors.

Patients were categorized into distinct risk groups for tMN based on TMNRS scores.

The score provides a practical method for identifying cancer patients at risk of tMN during routine clinical care.

Abstract

A prediction model for estimating risk of therapy-related myeloid neoplasms (tMNs), a late effect with a high mortality after chemotherapy and/or radiation, is currently unavailable. Ability to predict risk at initial cancer presentation can be key for early detection and risk mitigation.

Using SEER-Medicare linked database, 970 390 adults diagnosed with first primary cancer from 2000 to 2011 (with follow-up through 2015) were selected. The sample was divided into training (n = 582 234) and validation cohorts (n = 388 156). Various tMN risk factors were used for the development of tMN prediction model: the Therapy-Related Myeloid Neoplasm Risk Score (TMNRS). TMNRS was created as a simple arithmetic sum of independent predictors of tMN weighted according to the adjusted hazard ratio from the Cox proportional hazards analysis.

In addition to the known risk factors of chemotherapy and radiation exposure, history of autoimmune disease and granulocyte-colony stimulating factor exposure emerged as consistent predictors of tMN after each of the 5 cancers in the study. Cancer survivors were categorized into distinct risk groups with variable risk of tMN.

TMNRS provides a simple and convenient office-based mechanism to identify solid cancer patients at variable risks of tMN development. This risk assessment tool provides preliminary insights that may contribute to future research on the management of patients, particularly those receiving adjuvant therapies. Further investigation is required to fully evaluate its clinical utility and potential effects on patient care.

Figures